Date: 2013-04-17
Type of information: R&D agreement
Compound: respiratory drug discovery services
Company: Boehringer Ingelheim (Germany) Argenta (Galapagos subsidiary – UK Belgium)
Therapeutic area: Respiratory diseases
Type agreement: R&D
Action mechanism:
Disease: undisclosed
Details: * On April 17, 2013, Argenta, a Galapagos company that provides drug discovery services from target validation to development candidate nomination, has announced that it has signed a collaboration agreement with Boehringer Ingelheim. Under the terms of the agreement, Argenta will apply its extensive respiratory drug discovery services to an undisclosed target within Boehringer Ingelheim’s respiratory disease portfolio.
Financial terms:
Latest news: